We have recently demonstrated that activation of AMPK sensitizes PC3 prostate cancer cells to docetaxel [30]; therefore, we aimed to explore the expression pattern and activity of AMPK in docetaxel-androgen-resistant LN-NE cells. This evidence concerns the gene PRKAA1 and prostate cancer.